-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the Financial Associated Press (Shanghai, editor Shi Zhengcheng), before the market on Thursday, local time, Pfizer announced that it has signed a purchase order for the new crown oral drug Paxlovid with the US government, which also means that the drug's price for developed countries is also synchronized.
(Source: company official website)
According to the agreement signed by the two parties, the US government will purchase 10 million courses of Paxlovid, which will pay a total of 5.
In early November, Pfizer disclosed that Paxlovid was able to reduce the hospitalization or death probability of patients with new coronary pneumonia with mild to moderate symptoms and underlying diseases by 89% in experiments
In Thursday’s announcement, Pfizer also disclosed that it has signed pre-purchase agreements with several countries and has initiated bilateral contacts with about 100 countries around the world
It is worth mentioning that the US government has also signed a purchase agreement for the new crown oral drug with Merck previously, with a total contract value of US$2.
